Our blog
Resources and insights
The latest industry news, interviews, technologies, and resources.
Blog categories
News
EquiSeq Featured in Albuquerque Journal
ALBUQUERQUE, NEW MEXICO – January 11, 2026 EquiSeq was profiled in the Business section of the Albuquerque Journal on January 11, 2026. The article, by writer Hannah Garcia, described the company’s origins and the road ahead, based on interviews with Paul Szauter, Chief Scientific Officer; Madison Sanders, an equestrian who is a member of EquiSeq’s Board of Directors; and Jeremy Edwards, a scientist at the University of New Mexico. Coverage was prompted by the issuance of a second U.S. patent for DNA testing of horses to detect the predisposition to muscle disease. Please see the full article in the Albuquerque Journal.
Blog
Riding Through MIM: A Test of Perseverance
A lot of people think finding out the horse that you’ve poured so much blood, sweat and tears into has a muscle disorder is one of the worst things that could happen. Sometimes, that’s true. Other times, it’s a relief. It’s a relief just to finally have an answer. It’s not one that I would wish on someone. It’s hard and complicated to get under control and manage over all. But it is possible. And it is possible to keep them happy and healthy… It just takes trial and error and a whole lot of patience to get there. And then some more, to keep them there. I currently have two very different horses with MIM. One is a registered Paint Horse gelding, Scooter. The other is Warmblood mare, Verona, with a full German passport. Bless the mini mare for saving my sanity and not being a candidate…. although she does have Heaves (just as annoying to manage but SO MUCH easier). As one of my friend’s pointed out, the Horse Distribution System really just pointed at me and yelled “chronic illness for this one.” Let’s start with the Paint. Watch This Move Doc or Scooter is 19 years old and…
News
EquiSeq Announces Issuance of Second U.S. Patent to Detect Muscle Disease in Horses
ALBUQUERQUE, New Mexico – December 16, 2025 – EquiSeq Inc, a biotechnology company developing DNA tests for inherited muscle disease in horses, announced today that the United States Patent and Trademark Office has issued U.S. Patent Number 16/088,247, “Method of Detecting Inherited Equine Myopathy.” The patent includes claims covering specific genetic mutations that predispose to muscle disease in horses, allowing the design of a rational breeding program to reduce the incidence of equine muscle disease. The patent, and EquiSeq’s other patent, U.S. Patent Number 12,398,426, “Methods of Detecting Inherited Myopathies in Horses,” describe the use of DNA testing to identify damaging genetic variants in six different horse genes. The patented technology has been in commercial use since 2017, with over 15,000 horses tested. The test is sold directly to consumers, including horse owners, breeders, and veterinarians. The technology has been licensed by Generatio GmbH, a company in Germany that provides equine genetic testing for Europe. DNA testing is a well-established technology that works reliably on all DNA, regardless of the source. In the United States, EquiSeq uses allele-specific PCR, a rapid test that returns results quickly enough for a pre-purchase exam. In Germany, Generatio uses an Illumina BeadArray, a comprehensive test for tens of thousands of variants….
News
EquiSeq Holds First Webinar
ALBUQUERQUE, NEW MEXICO – November 13, 2025 EquiSeq held its first Decoding Horse Health webinar on Zoom on November 11, 2025. Madison Sanders (Elite Equine Marketplace and EquiSeq) interviewed Paul Szauter, PhD (EquiSeq’s Chief Scientific Officer) and Stephanie Carter, FNTP (Indigo Ancestral Health). The webinar focused on inherited muscle disease in horses. Dr. Szauter discussed the founding of the company, the research behind its patented tests, and methods used to evaluate scientific work, including review by patent examiners and the peer-reviewed scientific literature. Stephanie Carter, who recently published Managing Muscle Mayhem, discussed management of affected horses through diet and other means. She reported that some affected horses are able to return to work of some kind with proper management. People attending the webinar were able to ask questions. The panelists expressed hope that this webinar will facilitate communication between horse owners and their veterinarians on this emerging area of horse health. A video of the webinar is posted on the Decoding Horse Health channel on YouTube.
News
EquiSeq’s DNA Test Changes the Landscape
ALBUQUERQUE, NEW MEXICO – October 14, 2025 The October 2025 issue of Equine Business Magazine published an article on EquiSeq, describing its DNA test as changing the landscape in managing horse health. Madison Ruddy Sanders, founder of Elete Equine Marketplace and a member of EquiSeq’s Board of Directors, wrote the article, based on conversations with Paul Szauter, EquiSeq’s Chief Scientific Officer; Stephanie Carter, an equine nutritionist; and horse owners Wendee Walker and Charlene Shingleton. EquiSeq’s patented DNA tests identify horses at risk for a muscle disease before they develop symptoms. Unlike muscle biopsy, EquiSeq’s DNA test is noninvasive, only requiring a hair sample. The article is one of the outcomes of EquiSeq’s recent outreach to horse owners. Madison Sanders and Paul Szauter have interviewed horse owners via Zoom, offering the opportunity for horse owners to write guest blog posts for EquiSeq’s website. They are currently planning public webinars to address horse muscle disease.
Blog
An Elephant to Discuss in the Equestrian Community
I’m an amateur dressage rider, Animal Reiki Practitioner, and trail enthusiast looking for my next happy, healthy trail partner. That means I’m horse shopping, which should be an exciting experience! As of Summer 2025, I tested 19 horses for PSSM2/MIM as part of my pre-purchase process. These horses came from all backgrounds registered and grade. Draft crosses. Iberians. Morgans. Mustangs from the same herd. Even a grade Haflinger. Over half of the horses I tested carry one or more variants of PSSM2/MIM. The breeder of my affected horse, insisted the genes don’t guarantee clinical signs. Other skeptics say, “correlation doesn’t equal causation,” as if that explains away the welfare concerns many owners are seeing firsthand. Maybe if your horse is a companion, or breeding stock not in work, you’ll never know. If they’re only used for breeding, and get trimmed twice a year, the cracks in health might stay hidden. But once they’re asked to work, the signs of pain are revealed. Stiffness. Resentment. Resistance. And acting like just being a horse is hard. Many are dangerously explosive. A grouchy “pain face” might be the only clue. These horses struggle to trailer and settle into a new environment as well….
Blog
Muscles as Messengers: How Muscle Myopathies Are Revolutionizing Equine Health Care
After two decades in the veterinary medical field, I’ve witnessed countless treatment protocols, diagnostic advances, and management trends. Yet nothing has transformed my understanding of equine health quite like muscle myopathies. These complex conditions—PSSM1, MIM and its variants, MFM, MYHM, and so forth—have become unexpected catalysts, revealing fundamental truths about health that extend far beyond the horses they affect. What makes these conditions so instructive isn’t their complexity, it’s their honesty. Unlike many equine ailments that respond to pharmaceutical intervention, muscle myopathies strip away our comfortable reliance on medical management. They demand something more fundamental: a return to species-appropriate nutrition, natural movement patterns, and collaborative care that honors the whole horse. When Medicine Meets Its Match In my years as an equine nutrition professional, I’ve consulted on hundreds of muscle myopathy cases. The pattern is strikingly consistent: owners arrive having tried every supplement, every medication, every promise of a solution. Their horses continue to struggle. Not because the veterinary care was inadequate, but because these conditions require something medicine alone cannot provide. This is where beauty emerges from the burden. When conventional treatments offer minimal relief, we’re forced to examine our husbandry practices and whether our convenient systems serve the…
News
EquiSeq Announces Issuance of U.S. Patent to Detect Genetic Variants Causing Muscle Disease in Horses
ALBUQUERQUE, New Mexico – September 2, 2025 – EquiSeq Inc, a biotechnology company developing DNA tests for inherited muscle disease in horses, announced today that the United States Patent and Trademark Office has issued U.S. Patent Number 12,398,426, “Methods of Detecting Inherited Myopathies in Horses.” The patent includes claims covering specific genetic mutations that predispose to muscle disease in horses, allowing the design of a rational breeding program to reduce the incidence of equine muscle disease. The patent, and EquiSeq’s other patent, U.S. Patent Number 16/088,247, “Method of Detecting Inherited Equine Myopathy,” describe the use of DNA testing to identify damaging genetic variants in six different horse genes. The patented technology has been in commercial use since 2017, with thousands of horses tested. The test is sold directly to consumers, including horse owners, breeders, and veterinarians. The technology has been licensed by Generatio GmbH, a company in Germany that provides equine genetic testing for Europe. DNA testing is a well-established technology that works reliably on all DNA, regardless of the source. In the United States, EquiSeq uses allele-specific PCR, a rapid test that returns results quickly enough for a pre-purchase exam. In Germany, Generatio uses an Illumina BeadArray, a comprehensive test for tens of thousands of variants….
Blog
PSSM/MIM: The Dream Stealer
When you’ve exhausted all your resources and drained your back account, trying to find what is wrong with your horse, then what do you do? You dig a little deeper, research longer and keep asking questions. You get told you are crazy, your horse has got the better of you, and mostly you are making stuff up. You consider euthanasia but the good days come and you are left feeling hopeful and yet still frustrated. Here is the story of my beloved Tuned up Whiz it, aka Whizzy. Her current diagnosis is PSSM type 2 via biopsy and n/P2, n/Px n/MYHM via EquiSeq DNA testing. I met Whizzy the fall of 2009, she was 4 years old. Her price was way out of my range due to her breeding and intense training to be a reining horse. Whizzy just could not spin in one direction fast enough to meet the needs of the owner. She needed to move her fast as she had already bought another 2 year old. I took her on trial and I had x-rays that revealed some changes in her right front hoof, my farrier thought it no big deal. I made a super low offer…
Blog
K1 Allele of COL6A3
Introduction This blog post explores the K1 allele of the equine COL6A3 gene, which encodes Collagen type VI alpha 3 chain. Portions of this blog post serve as additional sources of information to supplement the COL6A3 Gene Page. The K1 allele of COL6A3 carries a missense mutation, shown below. The protein model XP_014595871.3 was used to assign amino acid positions. Figure 1. Alignment of partial COL6A3 protein sequences from horse, compared to the K1 variant. The position of the amino acid affected by the substitution is highlighted in red. We present data to support the hypothesis that the K1 allele of COL6A3 is damaging. The K1 variant (G1976A) substitutes an alanine for a glycine. The affected amino acid is in the triple-helical portion of COL6A3. The general sequence of this region in all collagens is GLY-X-Y, where every third amino acid is a glycine. The X and Y amino acids are generally poorly conserved. In the formation of the collagen triple-helical region, the glycine residues are points of contact between helices. Glycine has the smallest R group of any amino acid (a hydrogen atom). Other amino acids in these positions interfere with triple helix formation to some extent. For further discussion,…







